16 September 2026 editorial review · Trial
INHALE-1st: Afrezza for youth with newly diagnosed T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT07224321; RECRUITING; updated 2026-08-13; enrollment 100 (ESTIMATED); results not posted.
Endpoint comparison: Percentage of participants with Continuous Glucose Meter (CGM) measured time in range (TIR) ≥70% (13 weeks).
Sources for this record: INHALE-1st Afrezza For Youth With Newly-Diagnosed Type 1 Diabetes (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.